SEC Tracker
Get the app

Vivos Therapeutics VVOS

Vivos Therapeutics acquires assets

Form
8-K
Filed
Importance
Routine
  1. Entered into a Mutual Stock Purchase and Asset Exchange Agreement with SOD Sciences.
  2. Issued 12,000 shares of Series C Preferred Stock valued at $12M.
  3. Acquired 50% co-ownership interest in the ReBalU Protocol.
  4. No cash exchanged, no placement agents used.

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Vivos Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 3841 and related industry codes: the same peer list as the financial tables.

  1. Positron POSC public float $22M, Jun 30, 2025
  2. United Health Products UEEC public float $25M, Jun 30, 2025
  3. Allurion Technologies ALUR public float $21M, Jun 30, 2025
  4. Neuroone Medical Technologies NMTC public float $26M, Mar 31, 2025, over 18 months old
  5. Precision Optics POCI public float $26M, Dec 31, 2025